Stockscreener 앱 받기
9.75
2.01%
-0.20
전일 마감가:
$9.95
열려 있는:
$10.28
하루 거래량:
258.10K
Relative Volume:
1.47
시가총액:
$256.99M
수익:
$50.14M
순이익/손실:
$-35.38M
주가수익비율:
-6.9643
EPS:
-1.4
순현금흐름:
$-39.46M
1주 성능:
-7.76%
1개월 성능:
+11.68%
6개월 성능:
+5.63%
1년 성능:
-43.97%
1일 변동 폭
$9.53
$10.40
1주일 범위
$9.53
$11.00
52주 변동 폭
$7.51
$18.93
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
RCEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
9.75 | 256.99M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-24 | 개시 | D. Boral Capital | Buy |
| 2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-02 | 개시 | Piper Sandler | Overweight |
| 2020-08-27 | 개시 | BofA Securities | Buy |
| 2020-04-21 | 개시 | Oppenheimer | Outperform |
| 2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
Insider Buying: Robert Mcnamara Acquires 10,000 Shares of AVITA Medical Inc (RCEL) - GuruFocus.com
AVITA Medical, Inc. (NASDAQ:RCEL) Director Robert Mcnamara Purchases 10,000 Shares - MarketBeat
D. Boral Capital Has Lowered Expectations for AVITA Medical (NASDAQ:RCEL) Stock Price - MarketBeat
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know - MSN
Avita Medical director Robert McNamara purchases $100,900 in stock By Investing.com - Investing.com South Africa
AVITA Medical, Inc. (NASDAQ:RCEL) CFO Purchases $10,250.00 in Stock - MarketBeat
Avita medical CFO David O'Toole acquires $9,900 in common stock - Investing.com India
Avita Medical director Robert McNamara purchases $100,900 in stock - Investing.com
AVITA Medical, Inc. (RCEL): A Bull Case Theory - Insider Monkey
When (RCEL) Moves Investors should Listen - Stock Traders Daily
D. Boral Capital Reiterates Buy Rating for AVITA Medical (NASDAQ:RCEL) - MarketBeat
After Sales Rebound In January, AVITA Is Set Up For A Monster Year - Seeking Alpha
AVITA Medical (NASDAQ:RCEL) Posts Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
AVITA Medical's SWOT analysis: regenerative medicine firm's stock faces growth hurdles - Investing.com
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2024 Earnings Call Transcript - Insider Monkey
Avita Medical targets $3.5B TAM with expanded portfolio amid Cohealyx launch in 2025 - MSN
Avita medical director Suzanne Crowe buys $6,390 in stock - MSN
AVITA Medical Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Stro - GuruFocus.com
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Cantor maintains Avita stock Overweight with $19 target - MSN
AVITA Medical to Host Investor Webinar Briefing - The Manila Times
Inside AVITA Medical's 2024 Performance: CEO & CFO Reveal Growth Strategy - StockTitan
Analyst Expectations For AVITA Medical's Future - Benzinga
Avita Medical earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
AVITA Medical Inc (RCEL) Q4 Earnings: EPS of -$0.44 Misses Estimate, Revenue of $18.4M Falls Short - GuruFocus.com
Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12% -February 13, 2025 at 10:41 pm EST - Marketscreener.com
2 ASX All Ords shares soaring on strong full year results - The Motley Fool Australia
AVITA Medical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical (ASX:AVH) Reports Q4 and FY 2024 Financial Results - The Capital Club
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FDA Approves RECELL GO mini - MPO-mag
Wound Closure Devices Market to See Drastic Growth – Post 2025 | AVITA Medical, ConvaTec, Organogenesis - Newstrail
Trend Tracker for (RCEL) - Stock Traders Daily
AVITA gets FDA clearance for Cohealyx for wound care - MSN
Terry Bromley Chosen to Lead Imbed Biosciences - MPO-mag
FDA Clears AVITA Medical’s Cohealyx Dermal Matrix - MPO-mag
AVITA Medical (NASDAQ:RCEL) adds US$24m to market cap in the past 7 days, though investors from five years ago are still down 81% - Simply Wall St
JPMorgan Chase & Co. Acquires 8,985 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Avita medical director Suzanne Crowe buys $6,390 in stock By Investing.com - Investing.com UK
(RCEL) Investment Report - Stock Traders Daily
Avita Gets FDA Nod For Device - San Fernando Valley Business Journal
Wound Skin Substitutes Market Forecast to 2030: Chronic Wound Burden Spurs Growth in Advanced Wound Care Technologies - Yahoo Finance
Wound Skin Substitutes Market Forecast to 2030: Chronic - GlobeNewswire
FY2024 EPS Forecast for AVITA Medical Decreased by Analyst - Defense World
Cantor Fitzgerald Expects Weaker Earnings for AVITA Medical - MarketBeat
Brokers Set Expectations for AVITA Medical FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts AVITA Medical FY2025 Earnings - MarketBeat
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Avita Medical Inc 주식 (RCEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| O'Toole David D | CFO |
Feb 20 '25 |
Buy |
9.90 |
1,000 |
9,900 |
25,734 |
| O'Toole David D | CFO |
Feb 19 '25 |
Buy |
10.25 |
1,000 |
10,250 |
24,734 |
| Crowe Suzanne | Director |
Dec 09 '24 |
Buy |
13.15 |
486 |
6,391 |
36,912 |
| O'Toole David D | CFO |
Dec 05 '24 |
Buy |
12.46 |
975 |
12,152 |
23,734 |
| O'Toole David D | CFO |
May 30 '24 |
Buy |
8.90 |
1,000 |
8,900 |
19,734 |
| O'Toole David D | CFO |
Feb 28 '24 |
Buy |
17.39 |
1,250 |
21,738 |
18,734 |
1.16%
0.10%
자본화:
|
볼륨(24시간):